CD4 and meningeal tuberculosis: One randomized, double-blind, placebo-controlled trial compared immediate ART (initiated within 7 days of commencing tuberculosis treatment) with deferred ART (initiated after 2 months of tuberculosis treatment) in patients with HIV-associated TBM, with the average CD4 count in two groups less than 50 cells/μL [42].